Monthly Archives: January 2013

Will "Robust Pipeline" Yield More New Drugs?

Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in […]
Posted in Biotech, FDA, leadership, R&D, Regulatory | Tagged , , , , , , | Leave a comment

Why Don't Those Damn Marketers 'Do' Digital?

By Sven Awege. Over the last few years I’ve worked with pharma marketers trying to preach and teach the virtues of digital channels. It has been a thankless task, with bucket loads of blood, sweat, and tears of frustration. I have used a number of different techniques, from talking about the revolution in big forums […]
Posted in E-Media, Guest Blog, Sales, social media, Strategy | Tagged , , | 2 Comments

Pharma's Promotional Spend: What's the Right Target?

Global consultancy Cegedim has released its latest survey on how and where big Pharma puts its promotional dollar. Pharmaceutical Promotional Spend: Global Trends reports that spending in emerging markets significantly increased last year, while Europe and US declined slightly.  Although overall promotion spending remained flat worldwide at $90 billion, the US still accounts for the […]
Posted in Advertising, Emerging Markets, Europe, Global, Marketing, Meetings, Sales, social media, Strategy, Technology | Tagged , , , , , | Leave a comment

Crowd Sourcing: The Time Has Come

By Marylyn Donahue. Crowd sourcing is hardly new, not even for pharma. Pfizer launched the first ever clinical trial to recruit and communicate with patients entirely via the Internet in 2011. Although it did shut down earlier last year due to lack of participants. But that certainly doesn’t mean crowd sourcing (use of web-based technologies […]
Posted in Strategy, Technology | Tagged , , , , , , | Leave a comment

Pharma Still Doesn't Get Patient Groups

A survey of 600 patient groups worldwide conducted in late 2012 revealed that perceptions of the pharmaceutical industry soured in the past year, mainly due to issues of access, pricing, patient safety and transparency. The Corporate Reputation of Pharma in 2012—the Patient Perspective compared the reputations of 29 leading pharma companies around six different indicators. […]
Posted in Europe, Market Access, patient education, pricing, Safety, Strategy | Tagged , , | Leave a comment
  • Categories

  • Meta